Hi Denise,
Your right everyone should do their own D.D. and i took a few miniutes out of my busy shedule to find the following :
"Liquidity and Capital Resources
As of June 30, 2012, we had cash or cash equivalents of $63,243.
Net cash used in operating activities was $59,949 during the six month period ended June 30, 2012, compared to $61,150 for the six month period ended June 30, 2011. We anticipate that overhead costs in current operations will increase in the future once our research and development activities discussed above increase.
Cash flows provided or used in investing activities were $0 for the six month periods ended June 30, 2012 and 2011. Cash flows provided or used by financing activities were $62,500 for the six month period ended June 30, 2012 and $0 for the similar period in 2011.
We are not generating revenue from our operations, and our ability to implement our business plan for the future will depend on the future availability of financing. Such financing will be required to enable us to further develop our testing, research and development capabilities and continue operations. We intend to raise funds through private placements of our common stock, through short-term borrowing and by application for grants in conjunction with the Research Foundation of the State University of New York with whom we have contracted to perform testing of our Adva-27a drug. We estimate that we will require approximately $5 million in debt and/or equity capital to fully implement our business plan in the future and there are no assurances that we will be able to raise this capital. While we have engaged in discussions with various investment banking firms to provide us these funds, as of the date of this report we have not reached any agreement with any party that has agreed to provide us with the capital necessary to effectuate our business plan or otherwise enter into a strategic alliance to provide such funding. Our inability to obtain sufficient funds from external sources when needed will have a material adverse effect on our plan of operation, results of operations and financial condition.
Our cost to continue operations as they are now conducted is nominal, but these are expected to increase once we commence Phase I clinical trials. We do not have sufficient funds to cover the anticipated increase in these expenses. We need to raise additional funds in order to continue our existing operations, to initiate research and development activities, and to finance our plans to expand our operations for the next year. If we are successful in raising additional funds, our research and development efforts will continue and expand. "
Unless i'm wrong they will need cash soon !!! I think i will wait and buy more SBFM AT .15- 20 CENTS !!
F.P.
AI
Market Data 
Markets 
